PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP InhibitionYasir H. Ibrahim, José Baselga, Isabel T. Rubio et al.|Cancer Discovery|2012Cited by 622
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerCristina Cruz, Violeta Serra, Marta Castroviejo‐Bermejo et al.|Annals of Oncology|2018Cited by 424
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo‐Bermejo, Violeta Serra, Cristina Cruz et al.|EMBO Molecular Medicine|2018Cited by 271
BRCA in breast cancer: ESMO Clinical Practice GuidelinesJudith Balmañà, Fátima Cardoso, Orland Dı́ez et al.|Annals of Oncology|2011Cited by 229
BRCA1 and BRCA2 genetic testing—pitfalls and recommendations for managing variants of uncertain clinical significanceDiana Eccles, David E. Goldgar, Gillian Mitchell et al.|Annals of Oncology|2015Cited by 220